Navigation Links
DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - Dyax Corp. (Nasdaq:DYAX) announced today positive topline results from its Phase 3, placebo-controlled trial, EDEMA3, for its lead product candidate DX-88 (ecallantide), for hereditary angioedema (HAE). A webcast presentation of the EDEMA3 data is scheduled for Tuesday, April 17, 2007 at 12:30 p.m. ET.

DX-88, an internally discovered, recombinant, plasma kallikrein inhibitor, is in clinical trials for the treatment of acute attacks of HAE, a rare genetic disease characterized by episodes of acute swelling and inflammation. Statistically significant results (DX-88-treated patients versus placebo) were achieved for both the primary and secondary endpoints in the EDEMA3 trial.

The primary endpoint, symptom improvement at four hours measured by a Treatment Outcome Score (TOS) developed for HAE attacks, had a p-value of 0.021. The two secondary endpoints also demonstrated statistical significance. The patient reported assessment of individual symptom burden at four hours measured using the Mean Symptom Complex Severity score (MSCS) had a p-value of 0.024. Time to significant improvement in overall response (defined for this trial as the first time post dosing that the patient reported the symptom complex as "a lot better" or "resolved" within the first 4 hours) had a median time of 149 minutes for the DX-88 group versus greater than 4 hours for the placebo group (p=0.044). The overall safety results showed that DX-88 continues to be well tolerated. There were no drug-related serious adverse events. EDEMA3 is the largest successfully completed, placebo-controlled trial for this indication under a United States Investigational New Drug application.

"We are extremely excited about the outcome of this EDEMA3 trial," commented Henry E. Blair, Chairman and Chief Executive Officer of Dyax. "Based on the topline results of this study, the extensive clinical dat
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema
3. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
4. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
7. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
8. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
11. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
Post Your Comments:
(Date:5/17/2013)... 17, 2013 The power of plants to ... in which mankind depends on the plant kingdom, is ... exhibition Wild Medicine: Healing Plants Around ... view from May 18 through September 8, 2013. ... featured exhibition,s many attractions include a re-creation of the ...
(Date:5/17/2013)... , May 17, 2013  Lakeland Industries, Inc. (NASDAQ: ... protective clothing for industry, healthcare and to first responders ... its financial results for the fiscal 2013 fourth quarter ... 21, 2013 at stock market close and will conduct ... p.m. eastern. (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) ...
(Date:5/17/2013)... May 17, 2013  Orexigen® Therapeutics, Inc. (Nasdaq: ... overview at the UBS Global Healthcare Conference in ... May 22 nd at 11 a.m. Eastern Time. To ... presentation, please visit the Investor Relations section of the Company,s ... available for 14 days after the event. About ...
Breaking Medicine Technology:Wild Medicine On View at The New York Botanical Garden Through Sept. 8 2Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2
... 1, 2011 Deb Group today announced the ... the world,s first group monitoring system to report ... new innovation, hospitals can now immediately monitor compliance ... "Five Moments for Hand Hygiene." A stand-alone system, ...
... Echo Therapeutics, Inc. (OTC Bulletin Board: ... tCGM System as a non-invasive, wireless, transdermal continuous ... System for transdermal drug delivery, today announced that ... & Sullivan Technology Innovation Award in Pharmaceuticals and ...
Cached Medicine Technology:Deb Group Introduces First Real-time Hand Hygiene Group Monitoring System Based on World Health Organization Guidelines 2Deb Group Introduces First Real-time Hand Hygiene Group Monitoring System Based on World Health Organization Guidelines 3Echo Therapeutics Receives Frost & Sullivan's 2011 Technology Innovation Award 2Echo Therapeutics Receives Frost & Sullivan's 2011 Technology Innovation Award 3Echo Therapeutics Receives Frost & Sullivan's 2011 Technology Innovation Award 4
(Date:5/19/2013)... (PRWEB) May 19, 2013 Today, ... small business health insurance . Zane Benefits, ... employer sponsored health benefits, is the leader in ... health reimbursement arrangements . , According to ... the self-employed intrinsically know the value of small ...
(Date:5/19/2013)... The report “Feed Additives Market by Types, Livestock ... 2017” published by MarketsandMarkets, defines and segments the global ... the global volume and revenue for the animal feed ... for the global market with analysis of trends, opportunities, ... segmented and revenue is forecasted on the basis of ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Dr. Keith Chertok ... help fight their unhealthy gums and increase the chance of ... Laser Assisted New Attachment Procedure (LANAP) not only removes diseased ... and strengthens the jaw bone for dental implants. ... diseased gum tissue. It can also help stimulate the healthy ...
(Date:5/19/2013)... 19, 2013 Exciting new Skin Brushes ... reintroducing a great practice known through the ages but ... as dry body brushing, has so many benefits for ... Sublime Beauty®. "We love that circulation and lymphatic systems ... organ, the skin, is supported through Skin Brushing." , ...
(Date:5/19/2013)... 19, 2013 HealthEconomics.Com , the ... pleased to unveil a new and exciting service: HE-Xpo: ... a powerful array of real-time communication tools to expand ... and abroad. , HE-Xpo is powered by OnStream ... look and feel of being at a physical trade ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2Health News:Exciting New Skin Brushes at Sublime Beauty® Bring Health and Beauty Benefits; Celebrities and Models Know the Secret 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3
... HealthDay Reporter , THURSDAY, Aug. 5 (HealthDay News) ... and regions of the brain involved in pain processing, ... when there is no obvious cause, a new study ... six-minute fMRI brain scans, and compared their results to ...
... overcoat, pockets filled with stones, walked into a river in ... his shotgun to his head and pulled the trigger. Journalist ... later celebrated authors, all who University of Alberta history researcher ... not the fate of a group of 18th century writersknown ...
... for differences in eating habits of African Americans based on ... unexpected result: No matter what the blood sugar level was, ... Americans are 1.8 times more likely to develop Type 2 ... are non-Hispanic whites, according to federal health agencies. Obesity is ...
... August 5, 2010 A new study from researchers ... bowel (colon) preparation is the most effective method for ... eight hours of the end of preparation were associated ... eight hours after the end of preparation. Two different ...
... , WEDNESDAY, Aug. 4 (HealthDay News) -- In 2008, the ... a warning label about an increased risk of suicidal behaviors. ... studies that found patients taking the drugs showed about twice ... of more than 5 million patients contradicts the FDA,s findings. ...
... One of the challenges of prostate cancer surgery is ... is estimated to cause long-term sexual dysfunction in half ... surgeons at NewYork-Presbyterian Hospital/Columbia University Medical Center presents evidence ... cancer surgery may reduce the risk of damaging the ...
Cached Medicine News:Health News:More Clues To Fibromyalgia Pain 2Health News:More Clues To Fibromyalgia Pain 3Health News:Secularization of suicide meant callous mockery of writers' deaths 2Health News:Diabetes or not, dietary habits of Aftrican-Americans are similar 2Health News:Diabetes or not, dietary habits of Aftrican-Americans are similar 3Health News:Diabetes or not, dietary habits of Aftrican-Americans are similar 4Health News:Study shows splitting bowel preparation dosage is most effective cleansing method before colonoscopy 2Health News:Study shows splitting bowel preparation dosage is most effective cleansing method before colonoscopy 3Health News:Study shows splitting bowel preparation dosage is most effective cleansing method before colonoscopy 4Health News:Epilepsy Drugs Don't Raise Suicide Risk, Study Shows 2Health News:Epilepsy Drugs Don't Raise Suicide Risk, Study Shows 3Health News:Laser may reduce prostate surgery's sexual side effects 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 9 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 6 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 10 mm....
Medicine Products: